Hind Rafei

Hind Rafei practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Hind Rafei's NPI, 1962884809, was assigned on June 28, 2015. Hind Rafei holds Texas license S9207.

Hind Rafei's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Hind Rafei's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Hind Rafei practices. Vendor and product names are available with a free account.

Hematology and oncology is Hind Rafei's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Hind Rafei is licensed in Texas.

CMS data shows 207 Medicare services from Hind Rafei across 1 procedure code in 2024, for 36 Medicare patients. Medicare paid $19,264 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 36 Medicare patients who saw Hind Rafei in 2024. The largest group is 65 to 74, with 24 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 3.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Hind Rafei's median patient age at 35, with 63% women.

In 2024, Hind Rafei wrote 87 Medicare Part D claims for 18 patients. 82% of them were for generic drugs. CMS names the drug for 26 of them, across 2 drugs with 11 or more claims each, at $98,144 in total drug cost. In 2023, CMS named 25 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Hind Rafei for performance year 2024, reported as part of a group. Hind Rafei accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 47 papers to Hind Rafei, published from 2015 to 2025. 2017 was the busiest year, with 9. The most frequent topics are Killer Cells, Natural, Graft vs Host Disease and Hematopoietic Stem Cell Transplantation. Hind Rafei has published most often in Br J Haematol. Hind Rafei's most frequent co-authors are Katayoun Rezvani, MD, PhD, Elizabeth J. Shpall, MD and Paul L. Lin, MD.

CMS Open Payments shows 7 general payments to Hind Rafei from 7 drug and device companies from 2017 to 2019. Food and beverage make up the largest share, 100% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $115.